메뉴 건너뛰기




Volumn 41, Issue 3, 2008, Pages 229-237

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Update on defibrotide and other current investigational therapies

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DEFIBROTIDE; GEMTUZUMAB OZOGAMICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; OLIGONUCLEOTIDE; PLACEBO; PROSTAGLANDIN E1; RAPAMYCIN; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR; URSODEOXYCHOLIC ACID;

EID: 39349106820     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705899     Document Type: Review
Times cited : (107)

References (108)
  • 2
    • 0027478056 scopus 로고
    • Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
    • McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
    • (1993) Ann Intern Med , vol.118 , pp. 255-267
    • McDonald, G.B.1    Hinds, M.S.2    Fisher, L.D.3    Schoch, H.G.4    Wolford, J.L.5    Banaji, M.6
  • 3
    • 0032533633 scopus 로고    scopus 로고
    • Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party
    • Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604.
    • (1998) Blood , vol.92 , pp. 3599-3604
    • Carreras, E.1    Bertz, H.2    Arcese, W.3    Vernant, J.P.4    Tomas, J.F.5    Hagglund, H.6
  • 4
    • 0032620465 scopus 로고    scopus 로고
    • Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome
    • Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306-315.
    • (1999) Biol Blood Marrow Transplant , vol.5 , pp. 306-315
    • Lee, J.L.1    Gooley, T.2    Bensinger, W.3    Schiffman, K.4    McDonald, G.B.5
  • 5
    • 9144249706 scopus 로고    scopus 로고
    • Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients
    • Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. Blood 2004; 103: 78-84.
    • (2004) Blood , vol.103 , pp. 78-84
    • Hogan, W.J.1    Maris, M.2    Storer, B.3    Sandmaier, B.M.4    Maloney, D.G.5    Schoch, H.G.6
  • 6
    • 0029011780 scopus 로고
    • The syndrome of hepatic veno-occlusive disease after marrow transplantation
    • Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
    • (1995) Blood , vol.85 , pp. 3005-3020
    • Bearman, S.I.1
  • 7
    • 0037112813 scopus 로고    scopus 로고
    • Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients
    • Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E et al Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309.
    • (2002) Transplantation , vol.74 , pp. 1303-1309
    • Pihusch, R.1    Salat, C.2    Schmidt, E.3    Gohring, P.4    Pihusch, M.5    Hiller, E.6
  • 8
    • 0032410481 scopus 로고    scopus 로고
    • Prevention and treatment of hepatic venocclusive disease after high-dose cytoroductive therapy
    • Richardson P, Bearman SI. Prevention and treatment of hepatic venocclusive disease after high-dose cytoroductive therapy. Leuk Lymphoma 1998; 31: 267-277.
    • (1998) Leuk Lymphoma , vol.31 , pp. 267-277
    • Richardson, P.1    Bearman, S.I.2
  • 9
    • 20244365292 scopus 로고    scopus 로고
    • Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study
    • Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-1129.
    • (2000) Br J Haematol , vol.111 , pp. 1122-1129
    • Chopra, R.1    Eaton, J.D.2    Grassi, A.3    Potter, M.4    Shaw, B.5    Salat, C.6
  • 10
    • 0037114746 scopus 로고    scopus 로고
    • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome
    • Richardson PG, Murakami C, An Z, Warren D, Momtaz P, Hoppensteadt D et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
    • (2002) Blood , vol.100 , pp. 4337-4343
    • Richardson, P.G.1    Murakami, C.2    An, Z.3    Warren, D.4    Momtaz, P.5    Hoppensteadt, D.6
  • 11
    • 10744221943 scopus 로고    scopus 로고
    • Difibrotide in the treatment of children with veno-occlusive disease- (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention
    • Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D et al. Difibrotide in the treatment of children with veno-occlusive disease- (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189-195.
    • (2004) Bone Marrow Transplant , vol.33 , pp. 189-195
    • Corbacioglu, S.1    Greil, J.2    Peters, C.3    Wulffraat, N.4    Laws, H.J.5    Dilloo, D.6
  • 13
    • 33749443746 scopus 로고    scopus 로고
    • Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide
    • Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W et al Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006; 38: 547-553.
    • (2006) Bone Marrow Transplant , vol.38 , pp. 547-553
    • Corbacioglu, S.1    Honig, M.2    Lahr, G.3    Stohr, S.4    Berry, G.5    Friedrich, W.6
  • 14
    • 34347407602 scopus 로고    scopus 로고
    • Prophylactic defibrotide in allogeneic stem cell transplantation: Minimal morbidity and zero mortality from veno-occlusive disease
    • Dignan F, Gujral D, Ethell M, Evans S, Treleaven J, Morgan G et al Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007; 40: 79-82.
    • (2007) Bone Marrow Transplant , vol.40 , pp. 79-82
    • Dignan, F.1    Gujral, D.2    Ethell, M.3    Evans, S.4    Treleaven, J.5    Morgan, G.6
  • 15
    • 34249947838 scopus 로고
    • Selective susceptibility of hepatic endotbelial cells to dacarbazine toxicity, a model for hepatic venoocclusive disease
    • DeLeve LD, Kaplowitz N. Selective susceptibility of hepatic endotbelial cells to dacarbazine toxicity, a model for hepatic venoocclusive disease. Hepatology 1991; 14: 161A.
    • (1991) Hepatology , vol.14
    • DeLeve, L.D.1    Kaplowitz, N.2
  • 16
    • 0029809978 scopus 로고    scopus 로고
    • Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation
    • DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830-837.
    • (1996) Hepatology , vol.24 , pp. 830-837
    • DeLeve, L.D.1
  • 17
    • 0034021677 scopus 로고    scopus 로고
    • The effect of busulphan on the pharmaco-kinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity
    • Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al The effect of busulphan on the pharmaco-kinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
    • (2000) Bone Marrow Transplant , vol.25 , pp. 915-924
    • Hassan, M.1    Ljungman, P.2    Ringden, O.3    Hassan, Z.4    Oberg, G.5    Nilsson, C.6
  • 18
    • 33646504460 scopus 로고    scopus 로고
    • High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
    • de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94: 1226-1230.
    • (2006) Br J Cancer , vol.94 , pp. 1226-1230
    • de Jonge, M.E.1    Huitema, A.D.2    Beijnen, J.H.3    Rodenhuis, S.4
  • 19
    • 0028593325 scopus 로고
    • Parameters of.the fibrinolytic system in patients undergoing BMT: Elevation of. PAI-1 in veno-occlusive disease
    • Salat C, Holler E, Reinhardt B, Kolb HJ, Seeber B, Ledderose G et al Parameters of.the fibrinolytic system in patients undergoing BMT: elevation of. PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994; 14: 747-750.
    • (1994) Bone Marrow Transplant , vol.14 , pp. 747-750
    • Salat, C.1    Holler, E.2    Reinhardt, B.3    Kolb, H.J.4    Seeber, B.5    Ledderose, G.6
  • 20
    • 4243653730 scopus 로고    scopus 로고
    • Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide
    • Richardson P, Krishnan A, Wheelef C, Hoppensteadt D, Tuchin J, Fyfe H et al. Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide. Blood 1996; 88: 458a.
    • (1996) Blood , vol.88
    • Richardson, P.1    Krishnan, A.2    Wheelef, C.3    Hoppensteadt, D.4    Tuchin, J.5    Fyfe, H.6
  • 21
    • 4243382376 scopus 로고    scopus 로고
    • Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide [DF]
    • Richardson P, Hoppensteadt D, Elias A, Frei III E, Iacobelli M, Guinan E et al. Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide [DF]. Blood 1997; 90: 219a.
    • (1997) Blood , vol.90
    • Richardson, P.1    Hoppensteadt, D.2    Elias, A.3    Frei III, E.4    Iacobelli, M.5    Guinan, E.6
  • 22
    • 0003717434 scopus 로고    scopus 로고
    • Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide
    • Richardson PG, Hoppensteadt D, Elias AD, Kinchla N, Warren D, Iacobelli M et al. Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thromb Hemost 1999; 3185 (Suppl): 628.
    • (1999) Thromb Hemost , vol.3185 , Issue.SUPPL. , pp. 628
    • Richardson, P.G.1    Hoppensteadt, D.2    Elias, A.D.3    Kinchla, N.4    Warren, D.5    Iacobelli, M.6
  • 23
    • 0031909016 scopus 로고    scopus 로고
    • Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications
    • Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61-65.
    • (1998) Ann Hematol , vol.76 , pp. 61-65
    • Nurnberger, W.1    Michelmann, I.2    Burdach, S.3    Gobel, U.4
  • 24
    • 0030933936 scopus 로고    scopus 로고
    • Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant
    • Salat C, Holler E, Kolbe HJ, Brigitte R, Pihusch R, Wolfgang W et al Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 1997; 89: 2184-2188.
    • (1997) Blood , vol.89 , pp. 2184-2188
    • Salat, C.1    Holler, E.2    Kolbe, H.J.3    Brigitte, R.4    Pihusch, R.5    Wolfgang, W.6
  • 25
    • 18544367609 scopus 로고    scopus 로고
    • Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide
    • Lee JH, Lee KH, Kim S, Seol M, Park CJ, Chi HS et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002; 118: 1087-1094.
    • (2002) Br J Haematol , vol.118 , pp. 1087-1094
    • Lee, J.H.1    Lee, K.H.2    Kim, S.3    Seol, M.4    Park, C.J.5    Chi, H.S.6
  • 27
    • 20144366170 scopus 로고    scopus 로고
    • Transforming growth factor bota-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoietic stem cell transplantation
    • Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R. Transforming growth factor bota-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoietic stem cell transplantation. Thromb Res 2005; 116: 233-240.
    • (2005) Thromb Res , vol.116 , pp. 233-240
    • Pihusch, V.1    Pihusch, M.2    Penovici, M.3    Kolb, H.J.4    Hiller, E.5    Pihusch, R.6
  • 28
    • 0027193827 scopus 로고
    • Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
    • Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592-1598.
    • (1993) N Engl J Med , vol.328 , pp. 1592-1598
    • Anscher, M.S.1    Peters, W.P.2    Reisenbichler, H.3    Petros, W.P.4    Jirtle, R.L.5
  • 29
    • 0141532294 scopus 로고    scopus 로고
    • Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome
    • DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003; 38: 900-908.
    • (2003) Hepatology , vol.38 , pp. 900-908
    • DeLeve, L.D.1    Wang, X.2    Kanel, G.C.3    Ito, Y.4    Bethea, N.W.5    McCuskey, M.K.6
  • 32
    • 0036125693 scopus 로고    scopus 로고
    • Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)
    • DeLeve L, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
    • (2002) Semin Liver Dis , vol.22 , pp. 27-42
    • DeLeve, L.1    Shulman, H.M.2    McDonald, G.B.3
  • 33
    • 0038069155 scopus 로고    scopus 로고
    • Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation
    • Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598.
    • (2003) Mayo Clin Proc , vol.78 , pp. 589-598
    • Kumar, S.1    DeLeve, L.D.2    Kamath, P.S.3    Tefferi, A.4
  • 34
    • 0001980758 scopus 로고
    • Venocclusive disease of the liver following marrow transplantation
    • McDonald GB. Venocclusive disease of the liver following marrow transplantation. Marrow Transplant Rev 1993; 3: 49-56.
    • (1993) Marrow Transplant Rev , vol.3 , pp. 49-56
    • McDonald, G.B.1
  • 35
    • 13344250481 scopus 로고    scopus 로고
    • Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia
    • Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA et al Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75-80.
    • (1996) Bone Marrow Transplant , vol.17 , pp. 75-80
    • Rozman, C.1    Carreras, E.2    Qian, C.3    Gale, R.P.4    Bortin, M.M.5    Rowlings, P.A.6
  • 36
    • 10744231461 scopus 로고    scopus 로고
    • Positive selection for CD34 reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
    • Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34 reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545-550.
    • (2003) Exp Hematol , vol.31 , pp. 545-550
    • Moscardo, F.1    Urbano-Ispizua, A.2    Sanz, G.F.3    Brunet, S.4    Caballero, D.5    Vallejo, C.6
  • 37
    • 0025780243 scopus 로고
    • Regimen-related toxicity of a busulfancyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation
    • Nevill TJ, Barnett MJ, Klingemann HG, Reece DE, Shepherd JD, Phillips GL. Regimen-related toxicity of a busulfancyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
    • (1991) J Clin Oncol , vol.9 , pp. 1224-1232
    • Nevill, T.J.1    Barnett, M.J.2    Klingemann, H.G.3    Reece, D.E.4    Shepherd, J.D.5    Phillips, G.L.6
  • 38
    • 0031833915 scopus 로고    scopus 로고
    • Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation
    • Matute-Bello G, McDonald GD, Hinds MS, Schoch HG, Crawford SW. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21: 1125-1130.
    • (1998) Bone Marrow Transplant , vol.21 , pp. 1125-1130
    • Matute-Bello, G.1    McDonald, G.D.2    Hinds, M.S.3    Schoch, H.G.4    Crawford, S.W.5
  • 39
    • 27144472703 scopus 로고    scopus 로고
    • A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
    • Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E. Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404.
    • (2005) Haematologica , vol.90 , pp. 1396-1404
    • Cesaro, S.1    Pillon, M.2    Talenti, E.3    Toffolutti, T.4    Calore, E.5    Tridello, G.6
  • 40
    • 0028210717 scopus 로고
    • A randomized trial comparing busulfan with total body irradiation as conditioning in aliogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group
    • Ringden O, Ruutu T, Remberger M, Nikoskelainer L, Volin L, Vindelov T et al. A randomized trial comparing busulfan with total body irradiation as conditioning in aliogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
    • (1994) Blood , vol.83 , pp. 2723-2730
    • Ringden, O.1    Ruutu, T.2    Remberger, M.3    Nikoskelainer, L.4    Volin, L.5    Vindelov, T.6
  • 41
    • 0034960016 scopus 로고    scopus 로고
    • Busulfan levels are influenced by prior treatment and are associated with hepatic veno occiusive disease and early mortality but not with delayed complications following marrow transplantation
    • Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno occiusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121-1124.
    • (2001) Bone Marrow Transplant , vol.27 , pp. 1121-1124
    • Copelan, E.A.1    Bechtel, T.P.2    Avalos, B.R.3    Elder, P.J.4    Ezzone, S.A.5    Scholl, M.D.6
  • 42
    • 0037370735 scopus 로고    scopus 로고
    • Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoistic stem cell transplantation
    • McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoistic stem cell transplantation. Blood 2003; 101: 2043-2048.
    • (2003) Blood , vol.101 , pp. 2043-2048
    • McDonald, G.B.1    Slattery, J.T.2    Bouvier, M.E.3    Ren, S.4    Batchelder, A.L.5    Kalhorn, T.F.6
  • 43
    • 23244433213 scopus 로고    scopus 로고
    • Decreased incidence of hepatic NDeno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan+cyclophosphamide for allogeneic bone marrow transplantation
    • Lee JH, Choi SJ, Kim SE, Park CJ, Chi HS, Lee MS et al. Decreased incidence of hepatic NDeno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan+cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321-330.
    • (2005) Ann Hematol , vol.84 , pp. 321-330
    • Lee, J.H.1    Choi, S.J.2    Kim, S.E.3    Park, C.J.4    Chi, H.S.5    Lee, M.S.6
  • 44
    • 33745011812 scopus 로고    scopus 로고
    • Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantasion with targeted busulfan dosage
    • Clopes A, Sureda A, Sierra J, Queralto JM, Broto A, Farre R et al. Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantasion with targeted busulfan dosage. Eur J Haematol 2006; 77: 1-6.
    • (2006) Eur J Haematol , vol.77 , pp. 1-6
    • Clopes, A.1    Sureda, A.2    Sierra, J.3    Queralto, J.M.4    Broto, A.5    Farre, R.6
  • 45
    • 34250206633 scopus 로고    scopus 로고
    • Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality
    • McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13 853-862.
    • (2007) Biol Blood Marrow Transplant , vol.13 , pp. 853-862
    • McCune, J.S.1    Batchelder, A.2    Deeg, H.J.3    Gooley, T.4    Cole, S.5    Phillips, B.6
  • 46
    • 0042442407 scopus 로고    scopus 로고
    • Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
    • Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-1582.
    • (2003) Blood , vol.102 , pp. 1578-1582
    • Wadleigh, M.1    Richardson, P.G.2    Zahrieh, D.3    Lee, S.J.4    Cutler, C.5    Ho, V.6
  • 47
    • 23744511263 scopus 로고    scopus 로고
    • Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia
    • Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia. Blood 2005; 106: 1183-1188.
    • (2005) Blood , vol.106 , pp. 1183-1188
    • Arceci, R.J.1    Sande, J.2    Lange, B.3    Shannon, K.4    Franklin, J.5    Hutchinson, R.6
  • 48
    • 34147197520 scopus 로고    scopus 로고
    • Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An over-view from the research on adverse drug events and reports (RADAR) project
    • E-pub 7 September
    • McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An over-view from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31: 599-604. E-pub 7 September 2006.
    • (2006) Leuk Res 2007 , vol.31 , pp. 599-604
    • McKoy, J.M.1    Angelotta, C.2    Bennett, C.L.3    Tallman, M.S.4    Wadleigh, M.5    Evens, A.M.6
  • 50
    • 0034986714 scopus 로고    scopus 로고
    • Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection
    • Moscardo F, Sanz GF, de La Rubia J, Jimenez C, Saavedra S, Regadera A et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant 2001; 27: 983-988.
    • (2001) Bone Marrow Transplant , vol.27 , pp. 983-988
    • Moscardo, F.1    Sanz, G.F.2    de La Rubia, J.3    Jimenez, C.4    Saavedra, S.5    Regadera, A.6
  • 51
    • 10744231461 scopus 로고    scopus 로고
    • Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
    • Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545-550.
    • (2003) Exp Hematol , vol.31 , pp. 545-550
    • Moscardo, F.1    Urbano-Ispizua, A.2    Sanz, G.F.3    Brunet, S.4    Caballero, D.5    Vallejo, C.6
  • 52
    • 0041941520 scopus 로고    scopus 로고
    • Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    • Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601-1605.
    • (2003) Blood , vol.102 , pp. 1601-1605
    • Antin, J.H.1    Kim, H.T.2    Cutler, C.3    Ho, V.T.4    Lee, S.J.5    Miklos, D.B.6
  • 53
    • 20844456461 scopus 로고    scopus 로고
    • Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
    • Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-557.
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 551-557
    • Cutler, C.1    Henry, N.L.2    Magee, C.3    Li, S.4    Kim, H.T.5    Alyea, E.6
  • 54
    • 0036659926 scopus 로고    scopus 로고
    • Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide
    • Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide. Blood 2002; 100: 334-340.
    • (2002) Blood , vol.100 , pp. 334-340
    • Eissner, G.1    Multhoff, G.2    Gerbitz, A.3    Kirchner, S.4    Bauer, S.5    Haffner, S.6
  • 55
    • 0027259024 scopus 로고
    • Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist
    • Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993; 238: 327-334.
    • (1993) Eur J Pharmacol , vol.238 , pp. 327-334
    • Bianchi, G.1    Barone, D.2    Lanzarotti, E.3    Tettamanti, R.4    Porta, R.5    Moltrasio, D.6
  • 56
    • 0028347781 scopus 로고
    • Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro
    • Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 1994; 200: 933-936.
    • (1994) Biochem Biophys Res Commun , vol.200 , pp. 933-936
    • Bracht, F.1    Schror, K.2
  • 57
    • 0023800090 scopus 로고
    • Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man
    • Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988; 35: 151-156.
    • (1988) Eur J Clin Pharmacol , vol.35 , pp. 151-156
    • Coccheri, S.1    Biagi, G.2    Legnani, C.3    Bianchini, B.4    Grauso, F.5
  • 58
    • 0025001566 scopus 로고
    • Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins
    • Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V. Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins 1990; 40 337-350.
    • (1990) Prostaglandins , vol.40 , pp. 337-350
    • Berti, F.1    Rossoni, G.2    Biasi, G.3    Buschi, A.4    Mandelli, V.5
  • 59
    • 0028199746 scopus 로고
    • Defibrotide stimulates expression of thrombomodulin in human endothelial cells
    • Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Hemost 1994; 71: 507-510.
    • (1994) Thromb Hemost , vol.71 , pp. 507-510
    • Zhou, Q.1    Chu, X.2    Ruan, C.3
  • 60
    • 0003288420 scopus 로고    scopus 로고
    • Modulation of endothelium by heparins and defibrotide
    • Nicolaides A, Novo S eds, Elsevier Science B.V, Amsterdam
    • Fareed J. Modulation of endothelium by heparins and defibrotide. In: Nicolaides A, Novo S (eds). Advances in Vascular Pathology 1997. Elsevier Science B.V.: Amsterdam, 1997, pp 25-32.
    • (1997) Advances in Vascular Pathology 1997 , pp. 25-32
    • Fareed, J.1
  • 61
    • 0027258661 scopus 로고
    • Antithrombotic effect and clinical potential of defibrotide
    • Ulutin ON. Antithrombotic effect and clinical potential of defibrotide. Sem Thromb Hemost 1993, 19: 186-191.
    • (1993) Sem Thromb Hemost , vol.19 , pp. 186-191
    • Ulutin, O.N.1
  • 62
    • 0029866306 scopus 로고    scopus 로고
    • The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat
    • Jamieson A, Alcock P, Tuffin DP. The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis 1996; 10: 27-35.
    • (1996) Fibrinolysis , vol.10 , pp. 27-35
    • Jamieson, A.1    Alcock, P.2    Tuffin, D.P.3
  • 63
    • 0003296788 scopus 로고    scopus 로고
    • Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells
    • Falanga A, Marchetti M, Vignoli A, Barbui T. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood 1999; 94: 146a.
    • (1999) Blood , vol.94
    • Falanga, A.1    Marchetti, M.2    Vignoli, A.3    Barbui, T.4
  • 64
    • 85112366465 scopus 로고    scopus 로고
    • Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels
    • Falanga A, Marchetti M, Vignoli A, Barbui T. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels. Blood 2000; 96: 53a.
    • (2000) Blood , vol.96
    • Falanga, A.1    Marchetti, M.2    Vignoli, A.3    Barbui, T.4
  • 65
    • 0032147122 scopus 로고    scopus 로고
    • Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population
    • Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
    • (1998) Blood , vol.92 , pp. 737-744
    • Richardson, P.G.1    Elias, A.D.2    Krishnan, A.3    Wheeler, C.4    Nath, R.5    Hoppensteadt, D.6
  • 66
    • 0037114746 scopus 로고    scopus 로고
    • Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome
    • Richardson P, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt DA et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100 4337-4343.
    • (2002) Blood , vol.100 , pp. 4337-4343
    • Richardson, P.1    Murakami, C.2    Jin, Z.3    Warren, D.4    Momtaz, P.5    Hoppensteadt, D.A.6
  • 67
    • 34248187052 scopus 로고    scopus 로고
    • Defibrotide for the treatment of hepatic veno-occlusive disease in children
    • Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007; 48: 700-704.
    • (2007) Pediatr Blood Cancer , vol.48 , pp. 700-704
    • Bulley, S.R.1    Strahm, B.2    Doyle, J.3    Dupuis, L.L.4
  • 68
    • 39349084973 scopus 로고    scopus 로고
    • Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial
    • Richardson P. Soiffer R, Antin J, Jin Z, Kurtzberg J, Martin P et al Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial. Blood 2006; 108 178.
    • (2006) Blood , vol.108 , pp. 178
    • Richardson, P.1    Soiffer, R.2    Antin, J.3    Jin, Z.4    Kurtzberg, J.5    Martin, P.6
  • 70
    • 0027236877 scopus 로고
    • Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrov transplantation
    • Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrov transplantation. J Clin Oncol 1993; 11: 1729-1736.
    • (1993) J Clin Oncol , vol.11 , pp. 1729-1736
    • Bearman, S.I.1    Anderson, G.L.2    Mori, M.3    Hinds, M.S.4    Shulman, H.M.5    McDonald, G.B.6
  • 71
    • 85117737565 scopus 로고
    • Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure
    • letter to editor
    • Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004; 103: 1968; letter to editor.
    • (1968) Blood 2004 , vol.103
    • Versluys, B.1    Bhattacharaya, R.2    Steward, C.3    Cornish, J.4    Oakhill, A.5    Goulden, N.6
  • 72
    • 0025044352 scopus 로고
    • Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA)
    • Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5 439-441.
    • (1990) Bone Marrow Transplant , vol.5 , pp. 439-441
    • Baglin, T.P.1    Harper, P.2    Marcus, R.E.3
  • 73
    • 1842336845 scopus 로고    scopus 로고
    • Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
    • Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89 1501-1506.
    • (1997) Blood , vol.89 , pp. 1501-1506
    • Bearman, S.I.1    Lee, J.L.2    Baron, A.E.3    McDonald, G.B.4
  • 74
    • 0026606743 scopus 로고
    • Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation [letter] [see comments]
    • Laporte JP, Lesage S, Tilleul P, Najman A, Gorin NC. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation [letter] [see comments]. Lancet 1992; 339: 1057.
    • (1992) Lancet , vol.339 , pp. 1057
    • Laporte, J.P.1    Lesage, S.2    Tilleul, P.3    Najman, A.4    Gorin, N.C.5
  • 75
    • 0026723814 scopus 로고
    • Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation [letter; comment] [see comments]
    • Rosti G, Bandini G, Belardinelli A, Calod E, Tura S, Gherlinzoni F et al. Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation [letter; comment] [see comments]. Lancet 1992; 339: 1481-1482.
    • (1992) Lancet , vol.339 , pp. 1481-1482
    • Rosti, G.1    Bandini, G.2    Belardinelli, A.3    Calod, E.4    Tura, S.5    Gherlinzoni, F.6
  • 76
    • 0026795936 scopus 로고
    • Alteplase for hepatic veno-occlusive disease after bone marrow transplantation [letter; comment]
    • Ringden O, Wennberg L, Ericzon BG, Kallman R, Astrom M, Duraj F et al Alteplase for hepatic veno-occlusive disease after bone marrow transplantation [letter; comment]. Lancet 1992; 340: 546-547.
    • (1992) Lancet , vol.340 , pp. 546-547
    • Ringden, O.1    Wennberg, L.2    Ericzon, B.G.3    Kallman, R.4    Astrom, M.5    Duraj, F.6
  • 77
    • 0030037141 scopus 로고    scopus 로고
    • Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients
    • Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 1101-1104.
    • (1996) Bone Marrow Transplant , vol.17 , pp. 1101-1104
    • Leahey, A.M.1    Bunin, N.J.2
  • 79
    • 0029792765 scopus 로고    scopus 로고
    • Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: Impact on coagulation profile
    • Goldberg SL, Shubert J, Rao AK, Redei I, Klumpp TR, Mangan KF. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: Impact on coagulation profile. Bone Marrow Transplant 1996; 18: 633-636.
    • (1996) Bone Marrow Transplant , vol.18 , pp. 633-636
    • Goldberg, S.L.1    Shubert, J.2    Rao, A.K.3    Redei, I.4    Klumpp, T.R.5    Mangan, K.F.6
  • 80
    • 0029068719 scopus 로고
    • Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1
    • Higashigawa M, Watanabe M, Nishihara H, Tabata N, Azuma, E, Ido M et al. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1. Leuk Res 1995; 19: 477-480.
    • (1995) Leuk Res , vol.19 , pp. 477-480
    • Higashigawa, M.1    Watanabe, M.2    Nishihara, H.3    Tabata, N.4    Azuma, E.5    Ido, M.6
  • 81
    • 0029587501 scopus 로고
    • No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation
    • Hagglund H, Ringden O, Ljungman P. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplantation 1995; 27: 3535.
    • (1995) Transplantation , vol.27 , pp. 3535
    • Hagglund, H.1    Ringden, O.2    Ljungman, P.3
  • 82
    • 0030113020 scopus 로고    scopus 로고
    • Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): Efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment
    • Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW et al. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): Efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996; 11: 118-126.
    • (1996) J Korean Med Sci , vol.11 , pp. 118-126
    • Lee, J.H.1    Lee, K.H.2    Choi, J.S.3    Zang, D.Y.4    Kim, S.B.5    Kim, S.W.6
  • 83
    • 0028228501 scopus 로고
    • Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients
    • Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194-198.
    • (1994) Am J Hematol , vol.46 , pp. 194-198
    • Yu, L.C.1    Malkani, I.2    Regueira, O.3    Ode, D.L.4    Warrier, R.P.5
  • 84
    • 0033374251 scopus 로고    scopus 로고
    • Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation
    • Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1311-1314.
    • (1999) Bone Marrow Transplant , vol.24 , pp. 1311-1314
    • Schriber, J.1    Milk, B.2    Shaw, D.3    Christiansen, N.4    Baer, M.5    Slack, J.6
  • 85
    • 0032891890 scopus 로고    scopus 로고
    • Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)
    • Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999; 23: 803-807.
    • (1999) Bone Marrow Transplant , vol.23 , pp. 803-807
    • Kulkarni, S.1    Rodriguez, M.2    Lafuente, A.3    Mateos, P.4    Mehta, J.5    Singhal, S.6
  • 86
    • 0030864269 scopus 로고    scopus 로고
    • Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
    • Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
  • 87
    • 0033373299 scopus 로고    scopus 로고
    • Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer
    • Mertens R, Brost H, Granzen B, Nowak-Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr 1999; 158 (Suppl 3): S154-S158.
    • (1999) Eur J Pediatr , vol.158 , Issue.SUPPL. 3
    • Mertens, R.1    Brost, H.2    Granzen, B.3    Nowak-Gottl, U.4
  • 88
    • 2442670748 scopus 로고    scopus 로고
    • Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity
    • Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother 2004; 38 1053-1059.
    • (2004) Ann Pharmacother , vol.38 , pp. 1053-1059
    • Ibrahim, R.B.1    Peres, E.2    Dansey, R.3    Abidi, M.H.4    Abella, E.M.5    Klein, J.6
  • 89
    • 33745751942 scopus 로고    scopus 로고
    • Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/ denbrotide therapy
    • Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/ denbrotide therapy. Haematologica 2006; 91: 795-800.
    • (2006) Haematologica , vol.91 , pp. 795-800
    • Haussmann, U.1    Fischer, J.2    Eber, S.3    Scherer, F.4    Seger, R.5    Gungor, T.6
  • 90
    • 0024477970 scopus 로고
    • PGE1 accelerates thrombolysis by tissue plasminogen activator
    • Vaughan DE, Plavin SR, Schafer AI, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73 1213-1217.
    • (1989) Blood , vol.73 , pp. 1213-1217
    • Vaughan, D.E.1    Plavin, S.R.2    Schafer, A.I.3    Loscalzo, J.4
  • 91
    • 0031965306 scopus 로고    scopus 로고
    • Hepatic veno-occlusive disease in pediatric stem cell recipients: Successful treatment with continuous infusion of prostaglandin El and low-dose heparin
    • Schlegel PG, Haber HP, Beck J, Krumpelmann S, Handgretinger R, Bader P et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: Successful treatment with continuous infusion of prostaglandin El and low-dose heparin. Ann Hematol 1998; 76: 37-41.
    • (1998) Ann Hematol , vol.76 , pp. 37-41
    • Schlegel, P.G.1    Haber, H.P.2    Beck, J.3    Krumpelmann, S.4    Handgretinger, R.5    Bader, P.6
  • 92
    • 0027326608 scopus 로고
    • A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation
    • Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724-730.
    • (1993) Br J Haematol , vol.84 , pp. 724-730
    • Bearman, S.I.1    Shen, D.D.2    Hinds, M.S.3    Hill, H.A.4    McDonald, G.B.5
  • 93
    • 0026720385 scopus 로고
    • Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
    • Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992; 79: 2834-2840.
    • (1992) Blood , vol.79 , pp. 2834-2840
    • Attal, M.1    Huguet, F.2    Rubie, H.3    Huynh, A.4    Charlet, J.P.5    Payen, J.L.6
  • 94
    • 0025016567 scopus 로고
    • A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation
    • Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407-411.
    • (1990) Bone Marrow Transplant , vol.5 , pp. 407-411
    • Bearman, S.I.1    Hinds, M.S.2    Wolford, J.L.3    Petersen, F.B.4    Nugent, D.L.5    Slichter, S.J.6
  • 95
    • 0026348257 scopus 로고
    • Prophylactic heparin does not prevent liver veno-occclusive disease following autologous bone marrow transplantation
    • Marsa-Vila L, Gorin NC, Laporte JP. Prophylactic heparin does not prevent liver veno-occclusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346-352.
    • (1991) Eur J Haematol , vol.47 , pp. 346-352
    • Marsa-Vila, L.1    Gorin, N.C.2    Laporte, J.P.3
  • 96
    • 9244265492 scopus 로고    scopus 로고
    • Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients
    • Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J et al Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067-1071.
    • (1996) Transplantation , vol.61 , pp. 1067-1071
    • Or, R.1    Nagler, A.2    Shpilberg, O.3    Elad, S.4    Naparstek, E.5    Kapelushnik, J.6
  • 97
    • 17744388789 scopus 로고    scopus 로고
    • Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin
    • Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27: 627-633.
    • (2001) Bone Marrow Transplant , vol.27 , pp. 627-633
    • Simon, M.1    Hahn, T.2    Ford, L.A.3    Anderson, B.4    Swinnich, D.5    Baer, M.R.6
  • 98
    • 85047696457 scopus 로고    scopus 로고
    • A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation
    • Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137-143.
    • (2002) Bone Marrow Transplant , vol.29 , pp. 137-143
    • Park, S.H.1    Lee, M.H.2    Lee, H.3    Kim, H.S.4    Kim, K.5    Kim, W.S.6
  • 99
    • 0037765452 scopus 로고    scopus 로고
    • Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study
    • Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study. Bone Marrow Transplant 2003; 31: 1143-1149.
    • (2003) Bone Marrow Transplant , vol.31 , pp. 1143-1149
    • Forrest, D.L.1    Thompson, K.2    Dorcas, V.G.3    Couban, S.H.4    Pierce, R.5
  • 100
    • 0037765452 scopus 로고    scopus 로고
    • Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study
    • Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study Bone Marrow Transplant 2003; 31: 1143-1149.
    • (2003) Bone Marrow Transplant , vol.31 , pp. 1143-1149
    • Forrest, D.L.1    Thompson, K.2    Dorcas, V.G.3    Couban, S.H.4    Pierce, R.5
  • 101
    • 0034093330 scopus 로고    scopus 로고
    • The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veuo-occlusive disease after stem cell transplantation
    • Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A et al The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veuo-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-38.
    • (2000) Am J Hematol , vol.64 , pp. 32-38
    • Ohashi, K.1    Tanabe, J.2    Watanabe, R.3    Tanaka, T.4    Sakamaki, H.5    Maruta, A.6
  • 102
    • 0026779860 scopus 로고
    • Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients
    • Essell JH, Thompson JM, Harman GS, Halvorson RD, Snyder MJ, Callander NS et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992; 10: 367-372.
    • (1992) Bone Marrow Transplant , vol.10 , pp. 367-372
    • Essell, J.H.1    Thompson, J.M.2    Harman, G.S.3    Halvorson, R.D.4    Snyder, M.J.5    Callander, N.S.6
  • 103
    • 17344386370 scopus 로고    scopus 로고
    • Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial
    • Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128 (12 Part 1): 975-981.
    • (1998) Ann Intern Med , vol.128 , Issue.12 PART 1 , pp. 975-981
    • Essell, J.H.1    Schroeder, M.T.2    Harman, G.S.3    Halvorson, R.4    Lew, V.5    Callander, N.6
  • 104
    • 0037105367 scopus 로고    scopus 로고
    • Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation
    • Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
    • (2002) Blood , vol.100 , pp. 1977-1983
    • Ruutu, T.1    Eriksson, B.2    Remes, K.3    Juvonen, E.4    Volin, L.5    Remberger, M.6
  • 105
    • 0029154790 scopus 로고
    • Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immunological considerations
    • Schlitt HJ, Tischler HJ, Ringe B. Raddatz G, Maschek H, Dietrich H et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immunological considerations. Bone Marrow Transplant 1995; 16: 473-478.
    • (1995) Bone Marrow Transplant , vol.16 , pp. 473-478
    • Schlitt, H.J.1    Tischler, H.J.2    Ringe, B.3    Raddatz, G.4    Maschek, H.5    Dietrich, H.6
  • 106
    • 10144227048 scopus 로고    scopus 로고
    • Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease
    • Smith FO, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996; 18: 643-646.
    • (1996) Bone Marrow Transplant , vol.18 , pp. 643-646
    • Smith, F.O.1    Johnson, M.S.2    Scherer, L.R.3
  • 107
    • 0034171210 scopus 로고    scopus 로고
    • Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation
    • Alvarez R, Banares R, Casariego J, Echenagusia A, Simo G, Alvarez E et al. Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol 2000; 23: 177-180.
    • (2000) Gastroenterol Hepatol , vol.23 , pp. 177-180
    • Alvarez, R.1    Banares, R.2    Casariego, J.3    Echenagusia, A.4    Simo, G.5    Alvarez, E.6
  • 108
    • 0035202855 scopus 로고    scopus 로고
    • Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation
    • Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM et al. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 997-999.
    • (2001) Bone Marrow Transplant , vol.28 , pp. 997-999
    • Tefferi, A.1    Kumar, S.2    Wolf, R.C.3    Lacy, M.Q.4    Inwards, D.J.5    Gloor, J.M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.